RxDoctor Payments Data

Alexander Walters, MD

Ophthalmology · Asheville, NCNPI 1992208722

Payments from drug & device makers

$2,300in general payments, 2019–2025

Across 60 payments — averaging $38.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$539
  • Alcon$526
  • Bausch & Lomb Americas Inc.$339
  • Harrow Eye, LLC$259
  • Tarsus Pharmaceuticals, Inc.$230
  • Glaukos Corporation$159
  • plus $249 from 5 others

What the payments were for

  • Food & beverage$2,300100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,300 in reported general payments places this provider in the 60th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$654,400
Medicare patients
1,576
Services billed
4,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine72$95,737
XiidraLifitegrast35$51,976
XdemvyLotilaner13$23,692
Restasis MultidoseCyclosporine11$17,854
LumiganBimatoprost27$11,683
Latanoprost725$7,418
Cyclosporine14$5,990
Prednisolone Acetate157$5,942
CombiganBrimonidine Tartrate/Timolol16$5,524
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat208$2,925
Timolol Maleate270$2,726
Fluorometholone31$2,117
Loteprednol Etabonate13$2,015
Ketorolac Tromethamine57$1,613
Brimonidine Tartrate94$761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$339$51,97635 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$230$23,69213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →